FIRE-3 Trial Results - Dr. Scott Berry

Description: For more updates visit

Dr. Scott Berry with an update from ECC 2013 on the results of the FIRE-3 Trial. Trial Data Show Most Patients with Wild-Type RAS Metastatic Colorectal Cancer Benefit from First-Line FOLFIRI Plus Cetuximab Treatment.
Shared By : oncologyeducation
Posted on : 10/07/13
Added : 4 years ago
Category : Colorectal Cancer

More From oncologyeducation

Nothing found.